Thyroid cancer | ||||
Age | Control, adjusted HR | Thyroid cancer, adjusted HR | Without 131I treatment, adjusted HR | With 131I treatment, adjusted HR |
95% CI | ||||
≤49 | 1.00 | 1.18 (0.89–1.55) | 0.94 (0.57–1.57) | 1.27 (0.94–1.73) |
50–64 | 1.00 | 1.36 (0.98–1.90) | 1.43 (0.85–2.40) | 1.33 (0.91–1.96) |
>65 | 1.00 | 1.74 (0.86–3.52) | 2.83 (1.15–6.93) | 1.18 (0.45–3.09) |
98% CI | ||||
≤49 | 1.00 | 1.17 (0.84–1.64) | 0.94 (0.51–1.75) | 1.27 (0.87–1.84) |
50–64 | 1.00 | 1.38 (0.93–2.06) | 1.43 (0.76–2.70) | 1.36 (0.85–2.16) |
>65 | 1.00 | 1.69 (0.71–3.98) | 2.82 (0.95–8.40) | 1.14 (0.35–3.66) |
Adjusted for all comorbidities, hormone therapy, mammography, and ultrasonography.